First AD

Second AD

Panelists discuss the long-term study results for baricitinib in alopecia areata, noting that nearly 90% of patients maintained a SALT score of ≤20 from week 52 to week 104, with over 70% achieving a SALT score of ≤10, while also addressing the reported treatment-emergent adverse events (TEAEs), which were mostly mild to moderate, with common events including COVID-19 infection and upper respiratory tract infections.

Review of FDA Approved JAK Inhibitors for Alopecia Areata

Video content above is prompted by the following:

a. Baricitinib (n=194, long term study, Senna 2024): 

    i. Close to 90% of patients maintained SALT ≤20 from week 52 to week 104; SALT ≤10 was achieved by over 70% of patients; clinician- and patient-reported outcomes measurements for eyebrow and eyelash showed increase in response rates between weeks 52 and 104. 

    ii.TEAEs were reported in 76% of patients taking baricitinib. Most TEAEs were mild to moderate. Most common TEAEs (occurred in ≥5% patients) were COVID-19 infection, upper respiratory tract infection, and headache. One event of major adverse cardiovascular event was reported (<0.1% incidence rate).

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Baricitinib, in a long-term study involving 194 patients, demonstrated significant efficacy in maintaining hair regrowth, with nearly 90% achieving a SALT score of ≤20 and over 70% achieving a SALT score of ≤10 from week 52 to week 104. Both clinician- and patient-reported outcomes for eyebrow and eyelash regrowth improved during this period. Treatment-emergent adverse events (TEAEs) were reported in 76% of patients, predominantly mild to moderate, with the most common being COVID-19 infection, upper respiratory tract infection, and headache. A single major adverse cardiovascular event was noted.

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment